Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
'Any pharmaceutical company if they want to become global must be present in China,' said MD Kirti Ganorkar. Organon contributes over $800 million in annual…
Sun Pharma will acquire Organon for $14.00 per share in an all-cash deal valued at $11.75 billion in enterprise value. For 2025, Organon reported $6.2 billion…
PREM14A filed 06/01/2026. $120,000,000 termination fee payable by Organon; no reverse termination fee disclosed. Morgan Stanley fairness opinion dated April…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Sun Pharma agreed to acquire Organon & Co. for $14.00 per share in an all-cash transaction with an enterprise value of $11.75B, expanding Sun Pharma into Top-10 global biosimilars and a top-3 global women's health franchise.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. / Organon & Co. (this deal) | 2026 | $11.8B | — |
| Sun Pharmaceutical Industries Ltd. / Ranbaxy Laboratories Limited | 2014 | $4.0B | 66 |
| Sun Pharmaceutical Industries Ltd. / Ranbaxy Laboratories Limited | 2015 | $4.0B | 52 |
| Sun Pharmaceutical Industries Ltd. / DUSA Pharmaceuticals, Inc. | 2012 | $230M | 49 |
| Sun Pharmaceutical Industries Ltd. / URL Pharma, Inc. (generics business) | 2012 | $60M | 34 |
| Sun Pharmaceutical Industries Ltd. / Checkpoint Therapeutics, Inc. | 2025 | $355M | — |
| Sumitovant Biopharma / Myovant Sciences Ltd. | 2022 | $1.7B | 60 |
← Browse all deals · How we score deals
More: 2026 deals · Sun Pharmaceutical Industries Ltd. deals · Women's Health deals